Psyence Group and Psyence Biomedical Collaborate with Dr. Albert P. Garcia-Romeu
Toronto, March 10, 2025 – Psyence Group Inc. (Psyence Group), a Canadian-based life sciences company listed on the Canadian Securities Exchange under the symbol “PSYG,” is thrilled to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd. (Psyence Biomed), is collaborating with Dr. Albert P. Garcia-Romeu, a renowned neuroscientist and behavioral pharmacologist, to advance their research and development efforts.
Collaboration with Dr. Garcia-Romeu
Dr. Garcia-Romeu, who holds a Ph.D. in Neuroscience from the University of Barcelona, has extensive experience in the field of behavioral pharmacology and neuroscience research. He currently serves as the Chief Science Officer at the Beckley Foundation, a non-profit organization dedicated to advancing scientific research into psychoactive substances. He is also an Associate Professor in the Departments of Psychiatry and Behavioral Neurobiology at the University of Chicago.
The collaboration between Psyence Biomed and Dr. Garcia-Romeu will focus on the research and development of novel therapeutic approaches for various neurological and psychiatric disorders. The team will leverage Psyence Biomed’s proprietary psychedelic compounds and Dr. Garcia-Romeu’s expertise in behavioral pharmacology and neuroscience to design and execute preclinical and clinical studies.
Impact on the Individual
For individuals dealing with neurological and psychiatric disorders, this collaboration could bring about significant advancements in the development of new and effective treatments. Psychedelic compounds, such as those being researched by Psyence Biomed, have shown promise in treating conditions like depression, anxiety, and PTSD. Dr. Garcia-Romeu’s expertise in behavioral pharmacology and neuroscience will help ensure that these compounds are developed and tested in a rigorous and scientifically sound manner.
Impact on the World
The collaboration between Psyence Group and Psyence Biomed and Dr. Garcia-Romeu could have a profound impact on the world by contributing to the advancement of research into psychedelic compounds and their potential therapeutic applications. This could lead to the development of new treatments for neurological and psychiatric disorders, reducing the burden on individuals and healthcare systems worldwide.
Conclusion
Psyence Group’s partnership with Psyence Biomed and Dr. Albert P. Garcia-Romeu represents a significant step forward in the development of novel therapeutic approaches for neurological and psychiatric disorders. With Dr. Garcia-Romeu’s expertise in behavioral pharmacology and neuroscience, the team is well-positioned to design and execute rigorous preclinical and clinical studies, paving the way for potential breakthroughs in the treatment of various conditions. This collaboration not only holds promise for individuals dealing with these disorders but also for the global healthcare community as a whole.
- Psyence Group and its NASDAQ-listed associate, Psyence Biomedical, are collaborating with Dr. Albert P. Garcia-Romeu, a renowned neuroscientist and behavioral pharmacologist.
- Dr. Garcia-Romeu will contribute his expertise to the research and development of novel therapeutic approaches for neurological and psychiatric disorders using Psyence Biomed’s proprietary psychedelic compounds.
- This collaboration has the potential to lead to significant advancements in the treatment of various neurological and psychiatric disorders, reducing the burden on individuals and healthcare systems worldwide.
